A Study of ABT-751 in Patients With Colorectal Cancer

A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00073138

Enrollment

Registered

2003-11-18

Start date

2003-08-31

Completion date

2005-02-28

Last updated

2007-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with colorectal cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

Interventions

DRUGABT-751

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Colorectal cancer. * Recurrent tumor following treatment with irinotecan and/or oxaliplatin. * Able to tolerate normal activities of daily living. * Adequate bone marrow, kidney, and liver function.

Exclusion criteria

* Pregnant or breast feeding. * Anti-tumor therapy within 4 weeks of the start of ABT-751 administration. * Prior radiation therapy. * CNS metastasis.

Design outcomes

Primary

Measure	Time frame
Objective Response Rate in subjects with Recurrent Colorectal Cancer	1 year

Secondary

Measure	Time frame
Survival	2 years
Toxicities associated with treatment administration	1 year
Time to Tumor Progression (TTP)	1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026